VivoSeq
Oncology

Malignant Glioma

176

Pipeline Programs↗

22

Active Trials↗

60

Companies Involved↗

Malignant Glioma is a highly competitive landscape with 176 programs across 60 companies. The most active players are INSYS Therapeutics Inc, Alaunos Therapeutics, Tactical Therapeutics, Inc.. 17 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

15/100

Mech. Concentration

6/100

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

INSYS Therapeutics Inc

2 programs

Phase 1A

Alaunos Therapeutics

2 programs

Phase 1T

Tactical Therapeutics, Inc.

2 programs

Phase 1L

Lisata Therapeutics, Inc.

2 programs

Phase 1O

Oncolytics Biotech

1 program

Phase 1S

Samus Therapeutics, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical3

Lacosamide

UCB

Rivaroxaban

Wim Janssens

Etanidazole

National Cancer Institute (NCI)

Phase 166

Atezolizumab

Roche

Selinexor

Karyopharm Therapeutics Inc

Vandetanib

Genzyme, a Sanofi Company

Imiquimod

Bausch Health Americas, Inc.

Pembrolizumab

Merck & Co.

Phase 284

Valacyclovir

Glaxo Dba Glaxosmithkline

Carboplatin

Avyxa

Lenvatinib

Eisai

Antineoplaston A10

Burzynski Research Institute

Enzastaurin

Eli Lilly

Phase 36

Carmustine

Melissa K Accordino

Vincristine Sulfate

Eastern Cooperative Oncology Group

Lomustine

Azurity Pharmaceuticals

Β-Elemene

Peking Union Medical College Hospital

DOTATOC

Turku University Hospital

Approved17

Hydroxychloroquine

Alnylam Pharmaceuticals

Ibuprofen

Kenvue Brands

Palonosetron

Avyxa

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Aminolevulinic Acid

Biomed Industries, Inc.

Analysis

Modality Breakdown

83%

Small molecule

148 of 179 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody106%Cell therapy74%Vaccine74%Protein / enzyme63%Gene therapy1<1%

Small molecule leads; the ring shows all 179 classified programs, each share of the total. Modality classified for 100% of 200 pipeline programs.

Analysis

Trial Status

201

clinical trials

Completed135 · 67%
Unknown status21 · 10%
Terminated14 · 7%
Active, not recruiting10 · 5%
Withdrawn9 · 4%
Recruiting7 · 3%
Other5 · 2%

Clinical Trials

Trial Activity

201 trials

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Recruiting·—·Phase 1·NCT04547777·90 enrolled
Chronic CED of TPT for Recurrent Malignant Glioma
Recruiting·—·Phase 1·NCT06666712·6 enrolled
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Recruiting·HHopital Foch·Phase 2·NCT04945148·640 enrolled
Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)
Recruiting·LLee's Pharmaceutical Limited·Phase 3·NCT06160492·144 enrolled
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Recruiting·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·Phase 2·NCT06818331·20 enrolled
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Recruiting·BBeijing Neurosurgical Institute·Phase 1·NCT06585527·30 enrolled
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Recruiting·LLaminar Pharmaceuticals·Phase 1/2·NCT04299191·28 enrolled
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT02658279·27 enrolled
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
Active, not recruiting·—·Phase 1·NCT06614855·12 enrolled
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT02062827·29 enrolled
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Active, not recruiting·—·Phase 1·NCT03152318·62 enrolled
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03581292·38 enrolled
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Active, not recruiting·—·N/A·NCT07448480·1,000 enrolled
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT00268385·83 enrolled
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Active, not recruiting·—·Phase 1·NCT03299309·30 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)